Literature DB >> 29627387

Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma.

Arianna Barbetta1, Francisco Schlottmann2, Tamar Nobel1, David B Sewell1, Meier Hsu3, Kay See Tan3, Hans Gerdes4, Pari Shah4, Manjit S Bains1, Matthew Bott1, James M Isbell1, David R Jones1, Daniela Molena5.   

Abstract

BACKGROUND: Induction therapy has not been proven to be beneficial for patients with clinical T2N0 esophageal adenocarcinoma. Surgery alone is associated with disappointing survival for patients found to have nodal disease on final pathologic examination. The aim of this study was to identify factors that predict pathologic nodal involvement in patients with endoscopic ultrasound (EUS)-proven T2N0 esophageal adenocarcinoma.
METHODS: We retrospectively reviewed patients with EUS-staged T2N0 (uT2N0) esophageal adenocarcinoma treated with surgery alone. Final pathologic staging was compared with clinical staging. Demographic and clinicopathologic variables were evaluated as putative risk factors for nodal metastases. Logistic regression models were used to identify factors associated with nodal involvement. Kaplan-Meier analysis was performed to compare overall and recurrence-free survival between patients with (N+) and without (N-) nodal disease.
RESULTS: We identified 80 patients with uT2N0 esophageal adenocarcinoma treated with surgery alone. Clinical staging with EUS was inaccurate for 73 patients (91%). Twenty-eight patients (35%) had pathologic N+ disease at resection. Five-year overall survival was 67% for N- patients and 41% for N+ patients (p = 0.006). Recurrence-free survival was 65% for N- patients and 32% for N+ patients (p = 0.0043). Univariable analysis identified vascular invasion and neural invasion as risk factors for nodal metastasis. Multivariable analysis identified vascular invasion as an independent predictor of pathologic nodal involvement.
CONCLUSIONS: EUS is inaccurate for staging of T2N0 esophageal adenocarcinoma and often fails to identify nodal involvement. Identification of vascular invasion on preoperative biopsy should be explored as a prognostic marker to select patients for induction therapy.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29627387      PMCID: PMC6136647          DOI: 10.1016/j.athoracsur.2018.02.087

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  21 in total

1.  Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases.

Authors:  Roos E Pouw; Noor Heldoorn; Lorenza Alvarez Herrero; Fiebo J W ten Kate; Mike Visser; Olivier R Busch; Mark I van Berge Henegouwen; Kausilia K Krishnadath; Bas L Weusten; Paul Fockens; Jacques J Bergman
Journal:  Gastrointest Endosc       Date:  2011-01-26       Impact factor: 9.427

Review 2.  Nodal staging: number or site of nodes? How to improve accuracy? Is FNA always necessary? Junctional tumors--what's N and what's M?

Authors:  E Vazquez-Sequeiros
Journal:  Endoscopy       Date:  2006-06       Impact factor: 10.093

3.  T2N0M0 esophageal cancer.

Authors:  Thomas W Rice; David P Mason; Sudish C Murthy; Gregory Zuccaro; David J Adelstein; Lisa A Rybicki; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2007-01-09       Impact factor: 5.209

Review 4.  Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.

Authors:  Jennifer Q Zhang; Craig M Hooker; Malcolm V Brock; James Shin; Sue Lee; Remealle How; Noreli Franco; Helen Prevas; Alicia Hulbert; Stephen C Yang
Journal:  Ann Thorac Surg       Date:  2012-02       Impact factor: 4.330

5.  Pathologic lymph node ratio is a predictor of survival in esophageal cancer.

Authors:  Castigliano M Bhamidipati; George J Stukenborg; Christopher J Thomas; Christine L Lau; Benjamin D Kozower; David R Jones
Journal:  Ann Thorac Surg       Date:  2012-05-22       Impact factor: 4.330

6.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

Authors:  Christophe Mariette; Laetitia Dahan; Françoise Mornex; Emilie Maillard; Pascal-Alexandre Thomas; Bernard Meunier; Valérie Boige; Denis Pezet; William B Robb; Valérie Le Brun-Ly; Jean-François Bosset; Jean-Yves Mabrut; Jean-Pierre Triboulet; Laurent Bedenne; Jean-François Seitz
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

7.  Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer.

Authors:  O Pech; E Günter; F Dusemund; J Origer; D Lorenz; C Ell
Journal:  Endoscopy       Date:  2010-03-19       Impact factor: 10.093

8.  Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival.

Authors:  Traves D Crabtree; Wael N Yacoub; Varun Puri; Riad Azar; Jennifer Bell Zoole; G Alexander Patterson; A Sasha Krupnick; Daniel Kreisel; Bryan F Meyers
Journal:  Ann Thorac Surg       Date:  2011-03-24       Impact factor: 4.330

9.  Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.

Authors:  Magali Cabau; Guillaume Luc; Eric Terrebonne; Geneviève Belleanne; Véronique Vendrely; Antonio Sa Cunha; Denis Collet
Journal:  Am J Surg       Date:  2013-02-16       Impact factor: 2.565

10.  Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer.

Authors:  A Kutup; B-C Link; P G Schurr; T Strate; J T Kaifi; M Bubenheim; S Seewald; E F Yekebas; N Soehendra; J R Izbicki
Journal:  Endoscopy       Date:  2007-08       Impact factor: 10.093

View more
  3 in total

Review 1.  Management of clinical T2N0 esophageal cancer: a review.

Authors:  Patrick Vining; Thomas J Birdas
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

2.  An artificial neural network model predicting pathologic nodal metastases in clinical stage I-II esophageal squamous cell carcinoma patients.

Authors:  Xiao-Long Liu; Chen-Ye Shao; Lei Sun; Yi-Yang Liu; Li-Wen Hu; Zhuang-Zhuang Cong; Yang Xu; Rong-Chun Wang; Jun Yi; Wei Wang
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

3.  Optimal Treatment of cT2N0 Esophageal Carcinoma: Is Upfront Surgery Really the Way?

Authors:  Giovanni Capovilla; Lucia Moletta; Elisa Sefora Pierobon; Renato Salvador; Luca Provenzano; Gianpietro Zanchettin; Mario Costantini; Stefano Merigliano; Michele Valmasoni
Journal:  Ann Surg Oncol       Date:  2021-06-17       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.